Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
Provided By GlobeNewswire
Last update: Nov 10, 2025
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback
Read more at globenewswire.com
